20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
The market opportunity for legal psychedelics is in the hundreds of billions of dollars, “Shark Tank” judge Kevin O’Leary told the inaugural Benzinga Psychedelics Capital Conference on Tuesday.
Investors never get the opportunity to position themselves in a brand new sector, “Mr. Wonderful” told Benzinga founder and CEO Jason Raznick.
“This sector is medicine: FDA-approved, non-recreational use,” O’Leary said, speaking of psychedelics as a mental health treatment. “It’s a once-in-a-lifetime opportunity.”
Related Link: 'Psychedelics Companies Are Onto Something Extraordinary,' Says Kevin O'Leary: Meet Our Keynote Speakers
O’Leary’s Psychedelic Stock Picks: Legal psychedelics companies have collectively raised $2 billion and are in Phase 2 trials, said O’Leary.
He told the Benzinga conference at the Fontainebleau in Miami Beach that he first entered the space about three years ago.
O’Leary said he indexes the companies based on their focus on psilocybin, LSD and derivative molecules.
“I try and mitigate my risk based on trials.”
The “Shark Tank” judge said he’s overweight Mind Medicine (MindMed) Inc (NASDAQ:MNMD) and has exposure to Compass Pathways PLC (NASDAQ:CMPS) and ATAI Life Sciences NV (NASDAQ:ATAI).
“The minute one of them gets to Stage 3 [trials], you’re going to lift all the tides.”
Does Psychedelics Sector Need M&A? Raznick asked O’Leary whether big pharmaceutical companies are in psychedelics yet.
“I think Big Pharma’s starting to look at it,” O’Leary replied — and predicted Atai, Compass and MindMed will have to merge.
“They each need another $200 million by the time they get this to medicine,” he said.
Each segment of the market — LSD, microdosing, psilocybin, alternative molecules — is trying to address different afflictions, he said.
Another market exists for counseling, where psychedelics are used with a counselor, O’Leary said.
“I’m far more constructive on psychedelics for institutional capital than I am for cannabis.”
Related Link: EXCLUSIVE: Phyto Partners Launches Fourth Private Equity Fund
Benzinga CEO Jason Raznick, left, and "Shark Tank" judge Kevin O'Leary at the Benzinga Psychedelics Capital Conference Tuesday at the Fontainebleau in Miami Beach, Florida. Photo by Dez Smith.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!